CureVac, GSK's experimental COVID variant vaccine effective in mice -study

CureVac and GSK's second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as it seeks to catch up with rivals' development work. A study in mice showed that the bivalent vaccine candidate, designed to address the Beta and Delta variants of the coronavirus, elicited neutralizing antibody levels that were comparable to the monovalent vaccine candidates targeting only one of the variants.